Human Immunology Biosciences is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). HI-Bio is leading clinical immunology into its next chapter with more targeted therapies that target cellular drivers of disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/01/22 | $120,000,000 | Seed |
ARCH Venture Partners Jeito Capital Monograph Capital | undisclosed |
| 01/04/24 | $95,000,000 | Series B |
Alpha Wave Global ARCH Venture Partners Arkin Bio Ventures Jeito Capital Viking Global Investors | undisclosed |
